Deyuan Pharmaceutical: Rosuvastatin and Ezetimibe Tablets (I) Receives Drug Registration Certificate from NMPA

2026-03-21 04:34:21

Abstract generation in progress

Deyuan Pharmaceutical announced that on March 13, 2026, the company received the drug registration certificate from the National Medical Products Administration (NMPA) for the Resuvastatin Ezetimibe Tablets (I), which were filed under Category 4 chemical drugs, and it is deemed to have passed the consistency evaluation. Resuvastatin Ezetimibe Tablets are a lipid-lowering medication containing two complementary mechanisms: resuvastatin and ezetimibe. By inhibiting cholesterol absorption and synthesis, it reduces levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), while increasing high-density lipoprotein cholesterol (HDL-C).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.